Foldrx Drug Patent Portfolio
Foldrx owns 2 orange book drugs protected by 5 US patents Given below is the list of Foldrx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9770441 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole | 31 Aug, 2035 | Active |
| US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 19 Dec, 2026 | Active |
| US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 19 Dec, 2026 | Active |
| US8168663 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | 19 Dec, 2023 | Expired |
| US8653119 | Methods for treating transthyretin amyloid diseases | 19 Dec, 2023 | Expired |
Latest Legal Activities on Foldrx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Foldrx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Interim Patent Term Extension Granted | 15 Aug, 2025 | US7214695 |
| Interim Patent Term Extension Granted | 15 Aug, 2025 | US7214696 |
| Interim Patent Term Extension Granted | 15 Aug, 2025 | US7214695 |
| Interim Patent Term Extension Granted | 15 Aug, 2025 | US7214696 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 13 Aug, 2025 | US7214696 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 13 Aug, 2025 | US7214696 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 13 Aug, 2025 | US7214695 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 13 Aug, 2025 | US7214695 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9770441 |
| transaction for FDA Determination of Regulatory Review Period | 30 Oct, 2024 | US7214695 |
| transaction for FDA Determination of Regulatory Review Period | 30 Oct, 2024 | US7214695 |
| transaction for FDA Determination of Regulatory Review Period | 21 Oct, 2024 | US7214696 |
| transaction for FDA Determination of Regulatory Review Period | 21 Oct, 2024 | US7214695 |
| transaction for FDA Determination of Regulatory Review Period | 21 Oct, 2024 | US7214695 |
| transaction for FDA Determination of Regulatory Review Period | 21 Oct, 2024 | US7214696 |
Foldrx's Family Patents
Foldrx Drug List
Given below is the complete list of Foldrx's drugs and the patents protecting them.
1. Vyndamax
Vyndamax is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9770441 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
31 Aug, 2035
(9 years from now)
| Active |
| US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2026
(9 months from now)
| Active |
| US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2026
(9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyndamax's drug page
2. Vyndaqel
Vyndaqel is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2026
(9 months from now)
| Active |
| US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
19 Dec, 2026
(9 months from now)
| Active |
| US8168663 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
19 Dec, 2023
(2 years ago)
| Expired |
| US8653119 | Methods for treating transthyretin amyloid diseases |
19 Dec, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyndaqel's drug page